| Literature DB >> 27124244 |
Phisit Khemawoot1, Natthaphon Hunsakunachai1, Tosapol Anukunwithaya1, Kunan Bangphumi1, Boonsri Ongpipattanakul2, Weena Jiratchariyakul3, Ruedee Soawakontha4, Thanakorn Inthachart5, Thaweephol Dechatiwongse Na Ayudhya6, Sittichai Koontongkaew5, Orapan Poachanukoon6.
Abstract
Rhizomes of Zingiber cassumunar have been used for many years in traditional Thai medicine as an anti-inflammatory agent. The major bioactive component of this plant is Compound D [E-4-(3', 4'-dimethoxyphenyl)but-3-en-1-ol], which is a strong smooth muscle relaxant, and has antihistamine and anti-inflammatory actions. There is, however, incomplete information available for the pharmacokinetics of Compound D in mammals. In this study, we examined the pharmacokinetic profiles of Compound D in male Wistar rats. A standardized extract of Z. cassumunar containing 4 % w/w Compound D was administered intravenously at 25 mg/kg or by oral gavage at 25, 75, or 250 mg/kg to Wistar rats. Blood, tissues, urine, and feces were collected from 0 to 48 h after dosing and the level of Compound D was determined by liquid chromatography-tandem mass spectrometry. The concentration of Compound D ranged from 10-100 µg/L, reached a maximum approximately 0.15 h after oral dosing. Compound D exhibited an excellent tissue to plasma ratio, ranging from 1- to 1000 in several organs at 1-4 h after oral dosing. Less than 1 % of unchanged Compound D was excreted in the urine and feces. Further studies on tissue uptake and metabolite identification are required to obtain complete pharmacokinetic information and to develop appropriate dosing strategies of Compound D and the standardized extract of Z. cassumunar. Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27124244 DOI: 10.1055/s-0042-104658
Source DB: PubMed Journal: Planta Med ISSN: 0032-0943 Impact factor: 3.352